Hello there,
Welcome to the latest edition of The seqWell Scope!
The advent of gene editing technology is perhaps the most powerful and defining development in the last decade of biology. Since the original discovery and publication of CRISPR-based genome editing in 2013, applications related to this crucial tool have grown to encompass whole new areas of life science discovery, from crop engineering to the creation of life-saving medicines.
Two areas where seqWell is working to provide solutions that accelerate and improve the use of sequencing in CRISPR-related research and development are screening of synthetic gene editing constructs and gene editing QC.
Synthetic Constructs: In many cases, researchers need to identify and validate synthetic constructs that express Cas9 or DNA-modifying proteins (and their associated payload) in targeted cells occurs early in gene editing research. Our ExpressPlex™ Library Prep Kit, highlighted below, greatly simplifies this step. I encourage you to check out our Plasmid Sequencing page and our recently-hosted webinar with Octant Bio for a view of how this innovation has made a real-world impact.
Gene Editing QC: When cells are modified with gene editing technologies like CRISPR-Cas9, the resulting modified sequences can alter in unintended ways. Especially for potential therapeutic applications, the ability to measure and characterize the on- and off-target effects of a particular gene editing event is crucial. To address this, we created the Tagify UMI transposase-based set, which is being used in powerful gene editing QC methods like UDiTaS and RGEN-seq. You can learn more about this versatile new kit in our webinar with Georgia Giannoukos, Ph.D., from Editas Medicine, linked below.
Our team is excited to help accelerate the real-world applications of gene editing technology with sequencing tools and workflows that address different needs in this incredible new area. You can learn more about these efforts in the links below.
